Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Abstract Background There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effe...

Full description

Bibliographic Details
Main Authors: Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Nanoparticle albumin-bound paclitaxel
PD-1 inhibitor
Programmed cell death protein 1
Sintilimab
Soft tissue sarcoma
Angiosarcoma
Online Access:https://doi.org/10.1186/s12885-022-09176-1

Internet

https://doi.org/10.1186/s12885-022-09176-1

Similar Items